Chronic cutaneous lupus erythematosus+2
Not recruitingStudy on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy
Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy
- Disease:Chronic cutaneous lupus erythematosusCutaneous lupus erythematosus+1
- Substances:Litifilimab
France- Participants:18–64 years · 65+ years
- Substances:Litifilimab
- Sponsor:Biogen Idec Research Limited










